1
|
Adem C, Reynolds C, Ingle JN and
Nascimento AG: Primary breast sarcoma: Clinicopathologic series
from the Mayo Clinic and review of the literature. Br J Cancer.
91:237–241. 2004.PubMed/NCBI
|
2
|
Haberthür F, Feichter GE and Torhorst JK:
Sarcoma of the breast: What is the contribution of
immunohistochemistry and flow cytometry? Geburtshilfe Frauenheilkd.
53:811–813. 1993.(In German). View Article : Google Scholar : PubMed/NCBI
|
3
|
Krishnamurthy A: Primary breast
osteosarcoma: A diagnostic challenge. Indian J Nucl Med. 30:39–41.
2015. View Article : Google Scholar : PubMed/NCBI
|
4
|
Jernstrom P, Lindberg AL and Meland ON:
Osteogenic sarcoma of the mammary gland. Am J Clin Pathol.
40:5211963.PubMed/NCBI
|
5
|
Al Samaraee A, Angamuthu N and Fasih T:
Primary breast osteosarcoma: A case report and review of
literature. Scott Med J. 59:e1–e4. 2014. View Article : Google Scholar : PubMed/NCBI
|
6
|
Remadi S, Doussis-Anagnostopoulu I and
MacGee W: Primary osteosarcoma of the breast. Pathol Res Pract.
191:471–474. 1995. View Article : Google Scholar : PubMed/NCBI
|
7
|
Silver SA and Tavassoli FA: Primary
osteogenic sarcoma of the breast: A clinicopathologic analysis of
50 cases. Am J Surg Pathol. 22:925–933. 1998. View Article : Google Scholar : PubMed/NCBI
|
8
|
Jacobs TW, Gown AM, Yaziji H, Barnes MJ
and Schnitt SJ: Comparison of fluorscence in situ hybridization and
immunohistochemistry for the evaluation of HER-2/neu in breast
cancer. J Clin Oncol. 17:1974–1982. 1999.PubMed/NCBI
|
9
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar : PubMed/NCBI
|
10
|
Common Terminology Criteria for Adverse
Events v3.0 (CTCAE). 2006.http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf
|
11
|
Lagrange JL, Ramaioli A, Chateau MC, et
al: Sarcoma after radiation therapy: Retrospective
multiinstitutional study of 80 histologically confirmed cases.
Radiation therapist and pathologist groups of the Fédération
Nationale des Centres de Lutte Contre le Cancer. Radiology.
216:197–205. 2000. View Article : Google Scholar : PubMed/NCBI
|
12
|
Nwankwo N, Barbaryan A, Ali AM, et al:
Breast osteosarcoma 29 years after radiation therapy for epithelial
breast cancer. Case Rep Oncol. 6:367–372. 2013. View Article : Google Scholar : PubMed/NCBI
|
13
|
Lum WY and Jacobs L: Primary breast
sarcoma. Surg Clin North Am. 88:559–570. 2008. View Article : Google Scholar : PubMed/NCBI
|
14
|
Vorobiof G, Hariparsad G, Freinkel W, Said
H and Vorobiof DA: Primary osteosarcoma of the breast: A case
report. Breast J. 9:231–233. 2003. View Article : Google Scholar : PubMed/NCBI
|
15
|
Blanchard DK, Reynolds CA, Grant CS and
Donohue JH: Primary nonphylloides breast sarcomas. Am J Surg.
186:359–361. 2003. View Article : Google Scholar : PubMed/NCBI
|
16
|
Zhao J, Zhang X, Liu J and Li J: Primary
osteosarcoma of the breast with abundant chondroid matrix and
fibroblasts has a good prognosis: A case report and review of the
literature. Oncol Lett. 6:745–747. 2013.PubMed/NCBI
|
17
|
Szajewski M, Kruszewski WJ, Ciesielski M,
et al: Primary osteosarcoma of the breast: A case report. Oncol
Lett. 7:1962–1964. 2014.PubMed/NCBI
|
18
|
Cassier PA, Dufresne A, Fayette J, et al:
Emerging drugs for the treatment of soft tissue sarcomas. Expert
Opin Emerg Drugs. 12:139–153. 2007. View Article : Google Scholar : PubMed/NCBI
|
19
|
Shor AC, Agresta SV, D'Amato GZ and Sondak
VK: Therapeutic potential of directed tyrosine kinase inhibitor
therapy in sarcomas. Cancer Control. 15:47–54. 2008.PubMed/NCBI
|